CNS Saude Lda.
- Address
- lock Available on a paid plan
Immune System Diseases
Research at CNS Saude Lda. is dedicated to immune system diseases that affect the brain and spinal cord, with a particular focus on neuroinflammatory conditions such as multiple sclerosis. Ongoing studies evaluate the safety and disease‑modifying potential of novel biologics, aiming to reduce lesion formation and preserve neurological function.
- Primary progressive multiple sclerosis (PPMS)
- Evaluation of ocrelizumab in progressive disease
- Biomarker monitoring of cerebrospinal fluid inflammation
- Therapeutic approaches for multiple system atrophy
The site’s multidisciplinary team collaborates with international partners to bring emerging immunotherapies to patients, striving to improve long‑term outcomes in these challenging disorders.
Nervous System Diseases
At CNS Saude Lda. investigators explore a range of nervous system diseases, from movement disorders to genetic neurodegenerations. Trials target early disease stages to test novel agents that may slow progression, enhance motor control, and support cognitive health.
- Early Parkinson’s disease and motor fluctuation management
- Prodromal and early manifest Huntington’s disease
- Progressive supranuclear palsy (PSP) treatment evaluation
- Frontotemporal dementia (FTD) therapeutic investigation
- Assessment of ND0612 infusion and prasinezumab efficacy
By focusing on disease‑modifying strategies, the centre aims to deliver therapies that can alter the natural course of these neurodegenerative conditions.
Broad Neurological Research
The site conducts a wide‑range portfolio of studies that cannot be confined to a single category, encompassing cognitive decline, behavioral symptoms, and mixed‑etiology disorders. Research seeks to improve diagnostics, evaluate combination therapies, and address unmet needs across the dementia spectrum.
- Mild cognitive impairment and early Alzheimer’s disease
- Agitation associated with Alzheimer’s disease
- Combination treatment KarXT + KarX‑EC for behavioral symptoms
- Cognitive function assessment in semaglutide trials
- Long‑term safety of novel agents in neurodegenerative populations
These investigations reflect the centre’s commitment to advancing patient‑centered care through innovative therapeutic and diagnostic approaches.
Mental Disorders
CNS Saude Lda. places a strong emphasis on psychiatric manifestations that accompany neurodegenerative diseases, particularly psychosis and agitation in Alzheimer’s disease. Clinical trials test new antipsychotic compounds and multimodal regimens designed to reduce hallucinations, delusions, and disruptive behaviors.
- Psychosis associated with Alzheimer’s disease
- Hallucinations and delusions in Alzheimer’s disease psychosis
- Agitation in dementia of the Alzheimer’s type
- KarXT efficacy and tolerability
- AVP‑786 for agitation management
The goal is to improve quality of life for patients and caregivers by providing safer, more effective options for managing mental health symptoms in these vulnerable populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CNS Saude Lda.
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene | Bial R&D Investments S.A. | Phase II | Not Recruiting | Jul 2023 | Apr 2026 |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 5 | Unknown | 2024-05-09 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.